Moreover, the International Tuberous Sclerosis Complex Consensus Conference (ITSCCC) held in 2012 has recommended mTOR inhibitors as the first-line treatment for TSC-AML when enlarged to 3 cm or more15. The gene discussed is TSC1; the disease is acute myeloid leukemia.